Abstract
Targeted therapy enables patients with non-small cell lung cancer (NSCLC) with driver mutations prolongation of overall survival and improvement quality of life compared to chemotherapy. Crizotinib is one of biological drugs.
It is a tyrosine kinase inhibitor targeting ALK (anaplastic lymphoma kinase) gene rearrangement. Crizotinib is indicated for the first-line treatment of adults with ALK positive advanced NSCLC and for the treatment of adults with previously treated ALK positive advanced NSCLC.
It is also indicated for the treatment of ROS1 positive advanced NSCLC. Crizotinib has a good safety profile and tolerability.
Our article describes a clinical case report of ALK positive advanced NSCLC patient with rare choroidal metastasis that responds to crizotinib. Vision of our patient improved with crizotinib.
The quality of life was definitely better.